#psilocybin — Public Fediverse posts

Als Feministin bist du gezwungen, dich jederzeit in die Identität der #Hexe versetzen zu können, weil diese (Züchtigung) Zuschreibung extrem wirksam ist. Ich habe mich in diesem Setting für die Unterform "catholic witch" entschieden, weil jene am Wholesomsten und Abstraktesten sowie historisch einigermaßen akkurat ist; eingeübt habe ich diese Rolle auf #Psilocybin 🍄🍄‍🟫 im Bonner Münster. Nein ich habe in diesem gottlosen Zustand selbstverständlich nicht an der #Kommunion teilgenommen, sondern mit einer Nonne stehend das Treiben in der Gemeinde beobachtet und mit ihr den Friedensgruß getauscht.

Bitte diese Bundestag-Petition mitzeichnen und boosten!

Neubewertung der Einstufung von #Psilocybin und #Psilocin sowie deren Ester im BtMG vom 17.09.2025

https://epetitionen.bundestag.de/petitionen/_2025/_09/_17/Petition_186771.$$$.a.u.html

#Psychedelika

Bitte diese Bundestag-Petition mitzeichnen und boosten!

Neubewertung der Einstufung von #Psilocybin und #Psilocin sowie deren Ester im BtMG vom 17.09.2025

https://epetitionen.bundestag.de/petitionen/_2025/_09/_17/Petition_186771.$$$.a.u.html

#Psychedelika

Bitte diese Bundestag-Petition mitzeichnen und boosten!

Neubewertung der Einstufung von #Psilocybin und #Psilocin sowie deren Ester im BtMG vom 17.09.2025

https://epetitionen.bundestag.de/petitionen/_2025/_09/_17/Petition_186771.$$$.a.u.html

#Psychedelika

Bitte diese Bundestag-Petition mitzeichnen und boosten!

Neubewertung der Einstufung von #Psilocybin und #Psilocin sowie deren Ester im BtMG vom 17.09.2025

https://epetitionen.bundestag.de/petitionen/_2025/_09/_17/Petition_186771.$$$.a.u.html

#Psychedelika

Bitte diese Bundestag-Petition mitzeichnen und boosten!

Neubewertung der Einstufung von #Psilocybin und #Psilocin sowie deren Ester im BtMG vom 17.09.2025

https://epetitionen.bundestag.de/petitionen/_2025/_09/_17/Petition_186771.$$$.a.u.html

#Psychedelika

DATE: July 10, 2026 at 04:00PM
SOURCE: PSYPOST.ORG

** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------

TITLE: Psychedelic use linked to lower likelihood of migraines, twin study finds

URL: https://www.psypost.org/psychedelic-use-linked-to-lower-likelihood-of-migraines-twin-study-finds/

An analysis of Swedish Twin Registry data found that pairs of twins in which at least one twin reported psychedelic use had 50% lower odds of having had migraines compared to twin pairs with no psychedelic use history. Even within pairs of twins, the twin who reported using psychedelics had almost three times lower odds of having had migraines compared to their twin who did not use psychedelics. The paper was published in the Journal of Psychopharmacology.

Migraine is a neurological disorder characterized by recurrent attacks of moderate to severe headaches, often with additional sensory and digestive symptoms. The pain is commonly throbbing or pulsating and may affect only one side of the head, although it can occur on both sides. Attacks often worsen with physical activity and may last from several hours to several days.

Nausea, vomiting, sensitivity to light, sensitivity to sound, and sensitivity to smells are common accompanying symptoms. Some people experience an aura before or during the headache, which may include flashing lights, blind spots, tingling, speech difficulty, or other temporary neurological symptoms.

Migraine is thought to involve changes in brain activity, nerve signaling, and blood vessels, with genetic factors playing an important role. Common triggers include stress, lack of sleep, hormonal changes, skipped meals, dehydration, alcohol, certain foods, and changes in weather, although triggers differ among individuals.

Otto Simonsson, a researcher at the Karolinska Institute in Sweden, and colleagues evaluated the association between psychedelic use and migraine history. They note that some previous studies have indicated that psychedelic substances such as psilocybin (the active substance in “magic mushrooms”) and LSD show promise in the treatment of migraine. Some recent epidemiological studies partially replicated these findings on the potential effects of psychedelics on migraines and other headache disorders. The researchers wanted to see whether these findings held in samples of twins, which helps control for genetic and environmental factors.

The study authors combined data from three Swedish twin cohorts participating in the Swedish Twin Registry. These datasets included information on self-reported psychedelic use and migraine history. One group of twins was born between 1992 and 2005, the second group included twins born between 1985 and 1992, and the third group were twins born between 1958 and 1985.

Across all three groups, 50,726 participants answered questions about their past use of psilocybin or LSD. Of these, 47,452 also answered questions about their migraine history.

Results showed that there were 1,287 twins who reported using psilocybin or LSD, representing 2.5% of the sample. Among these, 420 were monozygotic (identical) twins. The researchers identified 271 identical twin pairs that differed in psychedelic use (one twin used psychedelics, the other did not), and 40 twin pairs that differed in both psychedelic use and migraine history.

Overall, the results showed that psychedelic use was associated with lower odds of migraine history. Participants who reported using psychedelics had 24% lower odds of having had migraines compared to participants who did not report using psychedelics. However, this association was only present in men and absent in women.

When identical twin pairs were compared, pairs in which at least one twin reported psychedelic use had 50% lower odds of having had migraines compared to twin pairs where neither twin reported psychedelic use. Within pairs, the difference in odds was even more striking—the twin who reported using psychedelics had almost three times lower odds of having had a migraine compared to the twin who did not. Again, when analyses were repeated on male participants only, results tended to stay the same, but associations were absent in female participants.

“The findings from this twin study suggest that psychedelics may be linked to a lower likelihood of migraine, with potential differences by sex. This warrants further investigation and highlights the importance of sex-specific analyses in future studies,” the study authors concluded.

The study contributes to the scientific knowledge about migraines. However, it should be noted that the design of this study does not allow any causal inferences to be derived from the results. Because of this, it remains unknown whether it is psychedelic use that reduces the risk of migraine or if it is that people who suffer from migraine are less likely to use illicit drugs. The reliance on self-reported data for medical diagnoses is another limitation.

The paper, “Associations between psychedelic use and migraine history in Swedish twins,” was authored by Otto Simonsson, Sunjuri Sun, Laura W. Wesseldijk, Fredrik Ullén, Walter Osika, and Miriam A. Mosing.

URL: https://www.psypost.org/psychedelic-use-linked-to-lower-likelihood-of-migraines-twin-study-finds/

-------------------------------------------------

Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org

Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot

-------------------------------------------------

#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #psychedelics #migraine #twinstudy #psilocybin #LSD #neurology #migraineprevention #sexdifferences #mentalhealthresearch #JournalofPsychopharmacology

DATE: July 10, 2026 at 04:00PM
SOURCE: PSYPOST.ORG

** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------

TITLE: Psychedelic use linked to lower likelihood of migraines, twin study finds

URL: https://www.psypost.org/psychedelic-use-linked-to-lower-likelihood-of-migraines-twin-study-finds/

An analysis of Swedish Twin Registry data found that pairs of twins in which at least one twin reported psychedelic use had 50% lower odds of having had migraines compared to twin pairs with no psychedelic use history. Even within pairs of twins, the twin who reported using psychedelics had almost three times lower odds of having had migraines compared to their twin who did not use psychedelics. The paper was published in the Journal of Psychopharmacology.

Migraine is a neurological disorder characterized by recurrent attacks of moderate to severe headaches, often with additional sensory and digestive symptoms. The pain is commonly throbbing or pulsating and may affect only one side of the head, although it can occur on both sides. Attacks often worsen with physical activity and may last from several hours to several days.

Nausea, vomiting, sensitivity to light, sensitivity to sound, and sensitivity to smells are common accompanying symptoms. Some people experience an aura before or during the headache, which may include flashing lights, blind spots, tingling, speech difficulty, or other temporary neurological symptoms.

Migraine is thought to involve changes in brain activity, nerve signaling, and blood vessels, with genetic factors playing an important role. Common triggers include stress, lack of sleep, hormonal changes, skipped meals, dehydration, alcohol, certain foods, and changes in weather, although triggers differ among individuals.

Otto Simonsson, a researcher at the Karolinska Institute in Sweden, and colleagues evaluated the association between psychedelic use and migraine history. They note that some previous studies have indicated that psychedelic substances such as psilocybin (the active substance in “magic mushrooms”) and LSD show promise in the treatment of migraine. Some recent epidemiological studies partially replicated these findings on the potential effects of psychedelics on migraines and other headache disorders. The researchers wanted to see whether these findings held in samples of twins, which helps control for genetic and environmental factors.

The study authors combined data from three Swedish twin cohorts participating in the Swedish Twin Registry. These datasets included information on self-reported psychedelic use and migraine history. One group of twins was born between 1992 and 2005, the second group included twins born between 1985 and 1992, and the third group were twins born between 1958 and 1985.

Across all three groups, 50,726 participants answered questions about their past use of psilocybin or LSD. Of these, 47,452 also answered questions about their migraine history.

Results showed that there were 1,287 twins who reported using psilocybin or LSD, representing 2.5% of the sample. Among these, 420 were monozygotic (identical) twins. The researchers identified 271 identical twin pairs that differed in psychedelic use (one twin used psychedelics, the other did not), and 40 twin pairs that differed in both psychedelic use and migraine history.

Overall, the results showed that psychedelic use was associated with lower odds of migraine history. Participants who reported using psychedelics had 24% lower odds of having had migraines compared to participants who did not report using psychedelics. However, this association was only present in men and absent in women.

When identical twin pairs were compared, pairs in which at least one twin reported psychedelic use had 50% lower odds of having had migraines compared to twin pairs where neither twin reported psychedelic use. Within pairs, the difference in odds was even more striking—the twin who reported using psychedelics had almost three times lower odds of having had a migraine compared to the twin who did not. Again, when analyses were repeated on male participants only, results tended to stay the same, but associations were absent in female participants.

“The findings from this twin study suggest that psychedelics may be linked to a lower likelihood of migraine, with potential differences by sex. This warrants further investigation and highlights the importance of sex-specific analyses in future studies,” the study authors concluded.

The study contributes to the scientific knowledge about migraines. However, it should be noted that the design of this study does not allow any causal inferences to be derived from the results. Because of this, it remains unknown whether it is psychedelic use that reduces the risk of migraine or if it is that people who suffer from migraine are less likely to use illicit drugs. The reliance on self-reported data for medical diagnoses is another limitation.

The paper, “Associations between psychedelic use and migraine history in Swedish twins,” was authored by Otto Simonsson, Sunjuri Sun, Laura W. Wesseldijk, Fredrik Ullén, Walter Osika, and Miriam A. Mosing.

URL: https://www.psypost.org/psychedelic-use-linked-to-lower-likelihood-of-migraines-twin-study-finds/

-------------------------------------------------

Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org

Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot

-------------------------------------------------

#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #psychedelics #migraine #twinstudy #psilocybin #LSD #neurology #migraineprevention #sexdifferences #mentalhealthresearch #JournalofPsychopharmacology

DATE: July 10, 2026 at 04:00PM
SOURCE: PSYPOST.ORG

** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------

TITLE: Psychedelic use linked to lower likelihood of migraines, twin study finds

URL: https://www.psypost.org/psychedelic-use-linked-to-lower-likelihood-of-migraines-twin-study-finds/

An analysis of Swedish Twin Registry data found that pairs of twins in which at least one twin reported psychedelic use had 50% lower odds of having had migraines compared to twin pairs with no psychedelic use history. Even within pairs of twins, the twin who reported using psychedelics had almost three times lower odds of having had migraines compared to their twin who did not use psychedelics. The paper was published in the Journal of Psychopharmacology.

Migraine is a neurological disorder characterized by recurrent attacks of moderate to severe headaches, often with additional sensory and digestive symptoms. The pain is commonly throbbing or pulsating and may affect only one side of the head, although it can occur on both sides. Attacks often worsen with physical activity and may last from several hours to several days.

Nausea, vomiting, sensitivity to light, sensitivity to sound, and sensitivity to smells are common accompanying symptoms. Some people experience an aura before or during the headache, which may include flashing lights, blind spots, tingling, speech difficulty, or other temporary neurological symptoms.

Migraine is thought to involve changes in brain activity, nerve signaling, and blood vessels, with genetic factors playing an important role. Common triggers include stress, lack of sleep, hormonal changes, skipped meals, dehydration, alcohol, certain foods, and changes in weather, although triggers differ among individuals.

Otto Simonsson, a researcher at the Karolinska Institute in Sweden, and colleagues evaluated the association between psychedelic use and migraine history. They note that some previous studies have indicated that psychedelic substances such as psilocybin (the active substance in “magic mushrooms”) and LSD show promise in the treatment of migraine. Some recent epidemiological studies partially replicated these findings on the potential effects of psychedelics on migraines and other headache disorders. The researchers wanted to see whether these findings held in samples of twins, which helps control for genetic and environmental factors.

The study authors combined data from three Swedish twin cohorts participating in the Swedish Twin Registry. These datasets included information on self-reported psychedelic use and migraine history. One group of twins was born between 1992 and 2005, the second group included twins born between 1985 and 1992, and the third group were twins born between 1958 and 1985.

Across all three groups, 50,726 participants answered questions about their past use of psilocybin or LSD. Of these, 47,452 also answered questions about their migraine history.

Results showed that there were 1,287 twins who reported using psilocybin or LSD, representing 2.5% of the sample. Among these, 420 were monozygotic (identical) twins. The researchers identified 271 identical twin pairs that differed in psychedelic use (one twin used psychedelics, the other did not), and 40 twin pairs that differed in both psychedelic use and migraine history.

Overall, the results showed that psychedelic use was associated with lower odds of migraine history. Participants who reported using psychedelics had 24% lower odds of having had migraines compared to participants who did not report using psychedelics. However, this association was only present in men and absent in women.

When identical twin pairs were compared, pairs in which at least one twin reported psychedelic use had 50% lower odds of having had migraines compared to twin pairs where neither twin reported psychedelic use. Within pairs, the difference in odds was even more striking—the twin who reported using psychedelics had almost three times lower odds of having had a migraine compared to the twin who did not. Again, when analyses were repeated on male participants only, results tended to stay the same, but associations were absent in female participants.

“The findings from this twin study suggest that psychedelics may be linked to a lower likelihood of migraine, with potential differences by sex. This warrants further investigation and highlights the importance of sex-specific analyses in future studies,” the study authors concluded.

The study contributes to the scientific knowledge about migraines. However, it should be noted that the design of this study does not allow any causal inferences to be derived from the results. Because of this, it remains unknown whether it is psychedelic use that reduces the risk of migraine or if it is that people who suffer from migraine are less likely to use illicit drugs. The reliance on self-reported data for medical diagnoses is another limitation.

The paper, “Associations between psychedelic use and migraine history in Swedish twins,” was authored by Otto Simonsson, Sunjuri Sun, Laura W. Wesseldijk, Fredrik Ullén, Walter Osika, and Miriam A. Mosing.

URL: https://www.psypost.org/psychedelic-use-linked-to-lower-likelihood-of-migraines-twin-study-finds/

-------------------------------------------------

Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org

Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot

-------------------------------------------------

#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #psychedelics #migraine #twinstudy #psilocybin #LSD #neurology #migraineprevention #sexdifferences #mentalhealthresearch #JournalofPsychopharmacology

80-year-old woman with Alzheimer's took mushrooms and started speaking again

https://www.microdos.in/en/research/alzheimers-case-report-psilocybin-speech

Comments: https://news.ycombinator.com/item?id=48858458

#HackerNews #Psilocybin #Healing #Mushrooms #Speech #Recovery

80-year-old woman with Alzheimer's took mushrooms and started speaking again

https://www.microdos.in/en/research/alzheimers-case-report-psilocybin-speech

Comments: https://news.ycombinator.com/item?id=48858458

#HackerNews #Psilocybin #Healing #Mushrooms #Speech #Recovery

80-year-old woman with Alzheimer's took mushrooms and started speaking again

https://www.microdos.in/en/research/alzheimers-case-report-psilocybin-speech

Comments: https://news.ycombinator.com/item?id=48858458

#HackerNews #Psilocybin #Healing #Mushrooms #Speech #Recovery

80-year-old woman with Alzheimer's took mushrooms and started speaking again

https://www.microdos.in/en/research/alzheimers-case-report-psilocybin-speech

Comments: https://news.ycombinator.com/item?id=48858458

#HackerNews #Psilocybin #Healing #Mushrooms #Speech #Recovery

80-year-old woman with Alzheimer's took mushrooms and started speaking again

https://www.microdos.in/en/research/alzheimers-case-report-psilocybin-speech

Comments: https://news.ycombinator.com/item?id=48858458

#HackerNews #Psilocybin #Healing #Mushrooms #Speech #Recovery

DATE: July 9, 2026 at 08:00PM
SOURCE: PSYPOST.ORG

** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------

TITLE: Luvesilocin: This new psychedelic drug could change how we treat postpartum depression

URL: https://www.psypost.org/luvesilocin-fda-trials-reveal-a-new-psychedelic-could-quickly-clear-postpartum-depression-symptoms/

About 1 in 5 women will experience depression and anxiety during pregnancy or in the year after giving birth. If untreated, a mother who has these conditions has a higher risk of birth complications, overall poorer health, impaired bonding and nurturing of her infant, and a higher risk of death by suicide.

But a new treatment moving through the Food and Drug Administration clinical trials process may be key to treating, or even curing, depression and anxiety in postpartum people. It is a newly named psychedelic, luvesilocin. It functions like psilocin, the psychoactive chemical within psilocybin mushrooms. It may be able to positively affect the unique hormonal shifts, brain changes and disconnection that can lead to these conditions like no existing treatments.

In prior studies of psilocybin, researchers have observed rapid improvement in symptoms – and sometimes a cure after a single dose – of conditions such as major depression and PTSD. In a recent FDA Phase 2 study of luvesilocin, we found similar improvements in postpartum depression.

I was the site investigator for the University of Colorado, one of 35 participating sites across the U.S. The study enrolled 84 postpartum women who were within a year of giving birth and ended in May 2025.

I have spent my career as a board-certified obstetrician-gynecologist contemplating how the prenatal experience shapes lifetime health. I have also followed the psychedelic data closely. I’ve been eager to find evidence-based pregnancy and postpartum applications of psychedelics, given these drugs’ promise in treating other mental health conditions.

Depression and anxiety’s impact on moms and babies

One drug that has been studied and enhanced our understanding of the way psychedelics work is MDMA, which is commonly known as ecstasy and causes a euphoric high.

According to peer-reviewed research published by Bessel van der Kolk in 2024, MDMA can lead to improvements in individuals being able to identify, describe and feel their feelings. Other improvements resulting from MDMA assisted therapy include more self-compassion and a broader desire and capacity for connection with others.

Connection, especially the earliest one between a mother and infant, plays one of the most significant roles in providing the foundation for humans to grow and flourish. Postpartum depression is often defined by disconnection and impaired bonding.

Children born to mothers with untreated depression and anxiety have a higher risk of falling behind on early developmental milestones. They may also have behavioral concerns, such as hyperactivity or ADHD, and are more likely to withdraw from social activities. They tend to report somatic complaints, such as body aches and pains in early childhood.

Children of mothers who had depression or anxiety during pregnancy are also at risk of these same conditions as they enter their teenage years. They have nearly twice the risk of these conditions compared to teenagers whose mothers did not have untreated depression and anxiety. This pattern means depression and anxiety can become a multigenerational cycle. But this cycle can be interrupted with adequate treatment and support.

Increased levels of the hormone oxytocin were found by researchers in the blood of depression study participants who were given MDMA, LSD and mescaline, which are all psychedelic drugs. The increase in oxytocin led to more feelings of trust, empathy and connection.

Oxytocin is a hormone produced in the part of the brain called the hypothalamus and is released from the pituitary gland into the bloodstream. It plays a critical role in birth and infant feeding. It also aids in the wiring and formation of human social brains.

Oxytocin is important in maternal bonding with an infant. Conversely, early childhood stressors, such as a mother suffering from mental illness, reduces oxytocin levels in children. This may be a contributor to adverse mental and physical health outcomes later in life.

In depression studies that involved men, psilocybin did not have as great of an impact as other psychedelic medications on oxytocin production. But there is reason to believe that oxytocin may play a greater role in postpartum patients because it’s levels are higher during birth and lactation than in other phases of life.

FDA study of psilocybin-like medication

In February 2026, the FDA granted luvesilocin breakthrough therapy status. This status is used to speed up the development of promising new medications for serious or life-threatening conditions. The drug received this status because our research found meaningful and rapid reductions in depression scores in those who received the treatment.

In the Phase 2 study, 77% of postpartum women who received a psychedelic dose, 30mg of luvesilocin, had significant improvement in their postpartum depression. Overall, 71% had no symptoms of postpartum depression seven days after the psychedelic session.

The purpose of an FDA Phase 2 study is to determine the effectiveness of an experimental medication on a particular disease or condition. In this case, the study is evaluating luvesilocin’s effect on postpartum depression scores and symptoms. In the group that received the placebo, a microdose of the drug, more than half experienced an improvement in their symptoms, but most still had some symptoms after seven days.

These are much higher response and remission rates than trials of the existing medications used for postpartum depression treatment. Existing treatments include selective serotonin reuptake inhibitors, known as SSRIs, and a medication called zuranolone. The latter is the only medication to have specific FDA approval for postpartum depression.

Access to psychedelic treatments

In 2023, the Colorado legislature passed the Natural Medicine Health Act. It offers a legal pathway for people to receive natural psychedelics, such as psilocybin mushrooms, in therapeutic settings. The first natural medicine healing centers opened in early 2026. Some locations advertise treatments for everything from postpartum depression to birth trauma.

Oregon has a similar state-regulated program. Numerous other states have different pathways toward legal psychedelic-assisted therapies and decriminalization of psilocybin-assisted therapy. Nationally, there was a recent federal executive order to accelerate action on treating serious mental illnesses. The order included mention of the use of psychedelic therapies.

Looking forward

By the end of 2026, Phase 3 of the luvesilocin trial for postpartum depression is slated to begin. Phase 3 trials are conducted to confirm the effectiveness and further evaluate the overall risks and benefits of a new medication. Each phase is an important regulatory step before a medication can be approved and available in clinical settings.

In Phase 3, 200 participants with postpartum depression will be recruited across participating sites. While I’m optimistic about the potential of this research, I believe its value can be established only through rigorous blinded clinical trials, objective data analysis, and conclusions and approval that are fully supported by the evidence.

Phase 3 will also include participants who are still breastfeeding. A study of luvesilocin during lactation in healthy volunteers demonstrated very low levels passed from the mother into breast milk. Thus, this medication would be considered safe for breastfeeding.

Luvesilocin may become a game-changing postpartum depression treatment medication in just a couple more years. On a much larger scale, psychedelic medicine could elevate our collective well-being and happiness, replacing systemic cycles of depression, anxiety, trauma and isolation with connectedness and compassion. These drugs could literally rewire our approach to trauma, addiction and how we relate to one another.

This article is republished from The Conversation under a Creative Commons license. Read the original article.

URL: https://www.psypost.org/luvesilocin-fda-trials-reveal-a-new-psychedelic-could-quickly-clear-postpartum-depression-symptoms/

-------------------------------------------------

Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org

Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot

-------------------------------------------------

#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #Luvesilocin #PostpartumDepression #PsychedelicTherapy #MaternalMentalHealth #PostpartumWellbeing #OxytocinConnection #MDMA #Psilocybin #MentalHealthInnovation #FDAClinicalTrials

DATE: July 9, 2026 at 08:00PM
SOURCE: PSYPOST.ORG

** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------

TITLE: Luvesilocin: This new psychedelic drug could change how we treat postpartum depression

URL: https://www.psypost.org/luvesilocin-fda-trials-reveal-a-new-psychedelic-could-quickly-clear-postpartum-depression-symptoms/

About 1 in 5 women will experience depression and anxiety during pregnancy or in the year after giving birth. If untreated, a mother who has these conditions has a higher risk of birth complications, overall poorer health, impaired bonding and nurturing of her infant, and a higher risk of death by suicide.

But a new treatment moving through the Food and Drug Administration clinical trials process may be key to treating, or even curing, depression and anxiety in postpartum people. It is a newly named psychedelic, luvesilocin. It functions like psilocin, the psychoactive chemical within psilocybin mushrooms. It may be able to positively affect the unique hormonal shifts, brain changes and disconnection that can lead to these conditions like no existing treatments.

In prior studies of psilocybin, researchers have observed rapid improvement in symptoms – and sometimes a cure after a single dose – of conditions such as major depression and PTSD. In a recent FDA Phase 2 study of luvesilocin, we found similar improvements in postpartum depression.

I was the site investigator for the University of Colorado, one of 35 participating sites across the U.S. The study enrolled 84 postpartum women who were within a year of giving birth and ended in May 2025.

I have spent my career as a board-certified obstetrician-gynecologist contemplating how the prenatal experience shapes lifetime health. I have also followed the psychedelic data closely. I’ve been eager to find evidence-based pregnancy and postpartum applications of psychedelics, given these drugs’ promise in treating other mental health conditions.

Depression and anxiety’s impact on moms and babies

One drug that has been studied and enhanced our understanding of the way psychedelics work is MDMA, which is commonly known as ecstasy and causes a euphoric high.

According to peer-reviewed research published by Bessel van der Kolk in 2024, MDMA can lead to improvements in individuals being able to identify, describe and feel their feelings. Other improvements resulting from MDMA assisted therapy include more self-compassion and a broader desire and capacity for connection with others.

Connection, especially the earliest one between a mother and infant, plays one of the most significant roles in providing the foundation for humans to grow and flourish. Postpartum depression is often defined by disconnection and impaired bonding.

Children born to mothers with untreated depression and anxiety have a higher risk of falling behind on early developmental milestones. They may also have behavioral concerns, such as hyperactivity or ADHD, and are more likely to withdraw from social activities. They tend to report somatic complaints, such as body aches and pains in early childhood.

Children of mothers who had depression or anxiety during pregnancy are also at risk of these same conditions as they enter their teenage years. They have nearly twice the risk of these conditions compared to teenagers whose mothers did not have untreated depression and anxiety. This pattern means depression and anxiety can become a multigenerational cycle. But this cycle can be interrupted with adequate treatment and support.

Increased levels of the hormone oxytocin were found by researchers in the blood of depression study participants who were given MDMA, LSD and mescaline, which are all psychedelic drugs. The increase in oxytocin led to more feelings of trust, empathy and connection.

Oxytocin is a hormone produced in the part of the brain called the hypothalamus and is released from the pituitary gland into the bloodstream. It plays a critical role in birth and infant feeding. It also aids in the wiring and formation of human social brains.

Oxytocin is important in maternal bonding with an infant. Conversely, early childhood stressors, such as a mother suffering from mental illness, reduces oxytocin levels in children. This may be a contributor to adverse mental and physical health outcomes later in life.

In depression studies that involved men, psilocybin did not have as great of an impact as other psychedelic medications on oxytocin production. But there is reason to believe that oxytocin may play a greater role in postpartum patients because it’s levels are higher during birth and lactation than in other phases of life.

FDA study of psilocybin-like medication

In February 2026, the FDA granted luvesilocin breakthrough therapy status. This status is used to speed up the development of promising new medications for serious or life-threatening conditions. The drug received this status because our research found meaningful and rapid reductions in depression scores in those who received the treatment.

In the Phase 2 study, 77% of postpartum women who received a psychedelic dose, 30mg of luvesilocin, had significant improvement in their postpartum depression. Overall, 71% had no symptoms of postpartum depression seven days after the psychedelic session.

The purpose of an FDA Phase 2 study is to determine the effectiveness of an experimental medication on a particular disease or condition. In this case, the study is evaluating luvesilocin’s effect on postpartum depression scores and symptoms. In the group that received the placebo, a microdose of the drug, more than half experienced an improvement in their symptoms, but most still had some symptoms after seven days.

These are much higher response and remission rates than trials of the existing medications used for postpartum depression treatment. Existing treatments include selective serotonin reuptake inhibitors, known as SSRIs, and a medication called zuranolone. The latter is the only medication to have specific FDA approval for postpartum depression.

Access to psychedelic treatments

In 2023, the Colorado legislature passed the Natural Medicine Health Act. It offers a legal pathway for people to receive natural psychedelics, such as psilocybin mushrooms, in therapeutic settings. The first natural medicine healing centers opened in early 2026. Some locations advertise treatments for everything from postpartum depression to birth trauma.

Oregon has a similar state-regulated program. Numerous other states have different pathways toward legal psychedelic-assisted therapies and decriminalization of psilocybin-assisted therapy. Nationally, there was a recent federal executive order to accelerate action on treating serious mental illnesses. The order included mention of the use of psychedelic therapies.

Looking forward

By the end of 2026, Phase 3 of the luvesilocin trial for postpartum depression is slated to begin. Phase 3 trials are conducted to confirm the effectiveness and further evaluate the overall risks and benefits of a new medication. Each phase is an important regulatory step before a medication can be approved and available in clinical settings.

In Phase 3, 200 participants with postpartum depression will be recruited across participating sites. While I’m optimistic about the potential of this research, I believe its value can be established only through rigorous blinded clinical trials, objective data analysis, and conclusions and approval that are fully supported by the evidence.

Phase 3 will also include participants who are still breastfeeding. A study of luvesilocin during lactation in healthy volunteers demonstrated very low levels passed from the mother into breast milk. Thus, this medication would be considered safe for breastfeeding.

Luvesilocin may become a game-changing postpartum depression treatment medication in just a couple more years. On a much larger scale, psychedelic medicine could elevate our collective well-being and happiness, replacing systemic cycles of depression, anxiety, trauma and isolation with connectedness and compassion. These drugs could literally rewire our approach to trauma, addiction and how we relate to one another.

This article is republished from The Conversation under a Creative Commons license. Read the original article.

URL: https://www.psypost.org/luvesilocin-fda-trials-reveal-a-new-psychedelic-could-quickly-clear-postpartum-depression-symptoms/

-------------------------------------------------

Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org

Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot

-------------------------------------------------

#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #Luvesilocin #PostpartumDepression #PsychedelicTherapy #MaternalMentalHealth #PostpartumWellbeing #OxytocinConnection #MDMA #Psilocybin #MentalHealthInnovation #FDAClinicalTrials

DATE: July 9, 2026 at 08:00PM
SOURCE: PSYPOST.ORG

** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------

TITLE: Luvesilocin: This new psychedelic drug could change how we treat postpartum depression

URL: https://www.psypost.org/luvesilocin-fda-trials-reveal-a-new-psychedelic-could-quickly-clear-postpartum-depression-symptoms/

About 1 in 5 women will experience depression and anxiety during pregnancy or in the year after giving birth. If untreated, a mother who has these conditions has a higher risk of birth complications, overall poorer health, impaired bonding and nurturing of her infant, and a higher risk of death by suicide.

But a new treatment moving through the Food and Drug Administration clinical trials process may be key to treating, or even curing, depression and anxiety in postpartum people. It is a newly named psychedelic, luvesilocin. It functions like psilocin, the psychoactive chemical within psilocybin mushrooms. It may be able to positively affect the unique hormonal shifts, brain changes and disconnection that can lead to these conditions like no existing treatments.

In prior studies of psilocybin, researchers have observed rapid improvement in symptoms – and sometimes a cure after a single dose – of conditions such as major depression and PTSD. In a recent FDA Phase 2 study of luvesilocin, we found similar improvements in postpartum depression.

I was the site investigator for the University of Colorado, one of 35 participating sites across the U.S. The study enrolled 84 postpartum women who were within a year of giving birth and ended in May 2025.

I have spent my career as a board-certified obstetrician-gynecologist contemplating how the prenatal experience shapes lifetime health. I have also followed the psychedelic data closely. I’ve been eager to find evidence-based pregnancy and postpartum applications of psychedelics, given these drugs’ promise in treating other mental health conditions.

Depression and anxiety’s impact on moms and babies

One drug that has been studied and enhanced our understanding of the way psychedelics work is MDMA, which is commonly known as ecstasy and causes a euphoric high.

According to peer-reviewed research published by Bessel van der Kolk in 2024, MDMA can lead to improvements in individuals being able to identify, describe and feel their feelings. Other improvements resulting from MDMA assisted therapy include more self-compassion and a broader desire and capacity for connection with others.

Connection, especially the earliest one between a mother and infant, plays one of the most significant roles in providing the foundation for humans to grow and flourish. Postpartum depression is often defined by disconnection and impaired bonding.

Children born to mothers with untreated depression and anxiety have a higher risk of falling behind on early developmental milestones. They may also have behavioral concerns, such as hyperactivity or ADHD, and are more likely to withdraw from social activities. They tend to report somatic complaints, such as body aches and pains in early childhood.

Children of mothers who had depression or anxiety during pregnancy are also at risk of these same conditions as they enter their teenage years. They have nearly twice the risk of these conditions compared to teenagers whose mothers did not have untreated depression and anxiety. This pattern means depression and anxiety can become a multigenerational cycle. But this cycle can be interrupted with adequate treatment and support.

Increased levels of the hormone oxytocin were found by researchers in the blood of depression study participants who were given MDMA, LSD and mescaline, which are all psychedelic drugs. The increase in oxytocin led to more feelings of trust, empathy and connection.

Oxytocin is a hormone produced in the part of the brain called the hypothalamus and is released from the pituitary gland into the bloodstream. It plays a critical role in birth and infant feeding. It also aids in the wiring and formation of human social brains.

Oxytocin is important in maternal bonding with an infant. Conversely, early childhood stressors, such as a mother suffering from mental illness, reduces oxytocin levels in children. This may be a contributor to adverse mental and physical health outcomes later in life.

In depression studies that involved men, psilocybin did not have as great of an impact as other psychedelic medications on oxytocin production. But there is reason to believe that oxytocin may play a greater role in postpartum patients because it’s levels are higher during birth and lactation than in other phases of life.

FDA study of psilocybin-like medication

In February 2026, the FDA granted luvesilocin breakthrough therapy status. This status is used to speed up the development of promising new medications for serious or life-threatening conditions. The drug received this status because our research found meaningful and rapid reductions in depression scores in those who received the treatment.

In the Phase 2 study, 77% of postpartum women who received a psychedelic dose, 30mg of luvesilocin, had significant improvement in their postpartum depression. Overall, 71% had no symptoms of postpartum depression seven days after the psychedelic session.

The purpose of an FDA Phase 2 study is to determine the effectiveness of an experimental medication on a particular disease or condition. In this case, the study is evaluating luvesilocin’s effect on postpartum depression scores and symptoms. In the group that received the placebo, a microdose of the drug, more than half experienced an improvement in their symptoms, but most still had some symptoms after seven days.

These are much higher response and remission rates than trials of the existing medications used for postpartum depression treatment. Existing treatments include selective serotonin reuptake inhibitors, known as SSRIs, and a medication called zuranolone. The latter is the only medication to have specific FDA approval for postpartum depression.

Access to psychedelic treatments

In 2023, the Colorado legislature passed the Natural Medicine Health Act. It offers a legal pathway for people to receive natural psychedelics, such as psilocybin mushrooms, in therapeutic settings. The first natural medicine healing centers opened in early 2026. Some locations advertise treatments for everything from postpartum depression to birth trauma.

Oregon has a similar state-regulated program. Numerous other states have different pathways toward legal psychedelic-assisted therapies and decriminalization of psilocybin-assisted therapy. Nationally, there was a recent federal executive order to accelerate action on treating serious mental illnesses. The order included mention of the use of psychedelic therapies.

Looking forward

By the end of 2026, Phase 3 of the luvesilocin trial for postpartum depression is slated to begin. Phase 3 trials are conducted to confirm the effectiveness and further evaluate the overall risks and benefits of a new medication. Each phase is an important regulatory step before a medication can be approved and available in clinical settings.

In Phase 3, 200 participants with postpartum depression will be recruited across participating sites. While I’m optimistic about the potential of this research, I believe its value can be established only through rigorous blinded clinical trials, objective data analysis, and conclusions and approval that are fully supported by the evidence.

Phase 3 will also include participants who are still breastfeeding. A study of luvesilocin during lactation in healthy volunteers demonstrated very low levels passed from the mother into breast milk. Thus, this medication would be considered safe for breastfeeding.

Luvesilocin may become a game-changing postpartum depression treatment medication in just a couple more years. On a much larger scale, psychedelic medicine could elevate our collective well-being and happiness, replacing systemic cycles of depression, anxiety, trauma and isolation with connectedness and compassion. These drugs could literally rewire our approach to trauma, addiction and how we relate to one another.

This article is republished from The Conversation under a Creative Commons license. Read the original article.

URL: https://www.psypost.org/luvesilocin-fda-trials-reveal-a-new-psychedelic-could-quickly-clear-postpartum-depression-symptoms/

-------------------------------------------------

Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org

Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot

-------------------------------------------------

#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #Luvesilocin #PostpartumDepression #PsychedelicTherapy #MaternalMentalHealth #PostpartumWellbeing #OxytocinConnection #MDMA #Psilocybin #MentalHealthInnovation #FDAClinicalTrials

DATE: July 7, 2026 at 09:37AM
SOURCE: PSYCHIATRIC TIMES

Direct article link at end of text block below.

New 6-month data from the phase 3 COMP006 trial show that COMP360 psilocybin delivers rapid, lasting relief in treatment-resistant depression. https://t.co/JEJw5t5WEh

Here are any URLs found in the article text:

https://t.co/JEJw5t5WEh

Articles can be found by scrolling down the page at Articles can be found at https://www.psychiatrictimes.com/news".

-------------------------------------------------

Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org

-------------------------------------------------

#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #psychotherapist #psilocybin #treatementresistantdepression #depressionresearch #phase3trial #mentalhealth breakthrough

DATE: July 7, 2026 at 09:37AM
SOURCE: PSYCHIATRIC TIMES

Direct article link at end of text block below.

New 6-month data from the phase 3 COMP006 trial show that COMP360 psilocybin delivers rapid, lasting relief in treatment-resistant depression. https://t.co/JEJw5t5WEh

Here are any URLs found in the article text:

https://t.co/JEJw5t5WEh

Articles can be found by scrolling down the page at Articles can be found at https://www.psychiatrictimes.com/news".

-------------------------------------------------

Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org

-------------------------------------------------

#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #psychotherapist #psilocybin #treatementresistantdepression #depressionresearch #phase3trial #mentalhealth breakthrough

DATE: July 7, 2026 at 09:37AM
SOURCE: PSYCHIATRIC TIMES

Direct article link at end of text block below.

New 6-month data from the phase 3 COMP006 trial show that COMP360 psilocybin delivers rapid, lasting relief in treatment-resistant depression. https://t.co/JEJw5t5WEh

Here are any URLs found in the article text:

https://t.co/JEJw5t5WEh

Articles can be found by scrolling down the page at Articles can be found at https://www.psychiatrictimes.com/news".

-------------------------------------------------

Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org

-------------------------------------------------

#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #psychotherapist #psilocybin #treatementresistantdepression #depressionresearch #phase3trial #mentalhealth breakthrough

Single dose of #magicmushroom #psychedelic can cause anatomical #brain changes, study finds
Participants took 25mg of #psilocybin, reporting deeper psychological insight and better wellbeing a month later
"We don't yet know what these changes mean, but we do note that overall, people showed positive psychological changes in this study, including improved wellbeing and mental flexibility." said Prof Robin Carhart-Harris, a neurologist at Univ of California, San Francisco.
https://www.theguardian.com/science/2026/may/05/magic-mushrooms-psychedelic-changes-brain-anatomy-psilocybin

Single dose of #magicmushroom #psychedelic can cause anatomical #brain changes, study finds
Participants took 25mg of #psilocybin, reporting deeper psychological insight and better wellbeing a month later
"We don't yet know what these changes mean, but we do note that overall, people showed positive psychological changes in this study, including improved wellbeing and mental flexibility." said Prof Robin Carhart-Harris, a neurologist at Univ of California, San Francisco.
https://www.theguardian.com/science/2026/may/05/magic-mushrooms-psychedelic-changes-brain-anatomy-psilocybin

Single dose of #magicmushroom #psychedelic can cause anatomical #brain changes, study finds
Participants took 25mg of #psilocybin, reporting deeper psychological insight and better wellbeing a month later
"We don't yet know what these changes mean, but we do note that overall, people showed positive psychological changes in this study, including improved wellbeing and mental flexibility." said Prof Robin Carhart-Harris, a neurologist at Univ of California, San Francisco.
https://www.theguardian.com/science/2026/may/05/magic-mushrooms-psychedelic-changes-brain-anatomy-psilocybin

Single dose of #magicmushroom #psychedelic can cause anatomical #brain changes, study finds
Participants took 25mg of #psilocybin, reporting deeper psychological insight and better wellbeing a month later
"We don't yet know what these changes mean, but we do note that overall, people showed positive psychological changes in this study, including improved wellbeing and mental flexibility." said Prof Robin Carhart-Harris, a neurologist at Univ of California, San Francisco.
https://www.theguardian.com/science/2026/may/05/magic-mushrooms-psychedelic-changes-brain-anatomy-psilocybin

Single dose of #magicmushroom #psychedelic can cause anatomical #brain changes, study finds
Participants took 25mg of #psilocybin, reporting deeper psychological insight and better wellbeing a month later
"We don't yet know what these changes mean, but we do note that overall, people showed positive psychological changes in this study, including improved wellbeing and mental flexibility." said Prof Robin Carhart-Harris, a neurologist at Univ of California, San Francisco.
https://www.theguardian.com/science/2026/may/05/magic-mushrooms-psychedelic-changes-brain-anatomy-psilocybin

Getting the yeast to make Psilocybin:
https://www.sciencedirect.com/science/article/pii/S109671761930401X
#yeast #psilocybin #entheogens

Getting the yeast to make Psilocybin:
https://www.sciencedirect.com/science/article/pii/S109671761930401X
#yeast #psilocybin #entheogens

wow. What a strange world we now live in.

"Brain-imaging research suggests that psilocybin temporarily breaks down the rigid, segregated boundaries that isolate large-scale brain networks from one another. By forcing surviving, under-utilized neural clusters to communicate in entirely new ways, the drug may make buried abilities accessible for a limited time."

https://neurosciencenews.com/psilocybin-memory-alzheimers-30084/

#alzheimers #magicmushrooms #psilocybin #MedicalTreatment

wow. What a strange world we now live in.

"Brain-imaging research suggests that psilocybin temporarily breaks down the rigid, segregated boundaries that isolate large-scale brain networks from one another. By forcing surviving, under-utilized neural clusters to communicate in entirely new ways, the drug may make buried abilities accessible for a limited time."

https://neurosciencenews.com/psilocybin-memory-alzheimers-30084/

#alzheimers #magicmushrooms #psilocybin #MedicalTreatment

wow. What a strange world we now live in.

"Brain-imaging research suggests that psilocybin temporarily breaks down the rigid, segregated boundaries that isolate large-scale brain networks from one another. By forcing surviving, under-utilized neural clusters to communicate in entirely new ways, the drug may make buried abilities accessible for a limited time."

https://neurosciencenews.com/psilocybin-memory-alzheimers-30084/

#alzheimers #magicmushrooms #psilocybin #MedicalTreatment

wow. What a strange world we now live in.

"Brain-imaging research suggests that psilocybin temporarily breaks down the rigid, segregated boundaries that isolate large-scale brain networks from one another. By forcing surviving, under-utilized neural clusters to communicate in entirely new ways, the drug may make buried abilities accessible for a limited time."

https://neurosciencenews.com/psilocybin-memory-alzheimers-30084/

#alzheimers #magicmushrooms #psilocybin #MedicalTreatment

wow. What a strange world we now live in.

"Brain-imaging research suggests that psilocybin temporarily breaks down the rigid, segregated boundaries that isolate large-scale brain networks from one another. By forcing surviving, under-utilized neural clusters to communicate in entirely new ways, the drug may make buried abilities accessible for a limited time."

https://neurosciencenews.com/psilocybin-memory-alzheimers-30084/

#alzheimers #magicmushrooms #psilocybin #MedicalTreatment

Transient multidomain functional improvement in advanced Alzheimer’s disease following high-dose #psilocybin-containing mushroom administration: a #case #report

https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2026.1813281/full

Transient multidomain functional improvement in advanced Alzheimer’s disease following high-dose #psilocybin-containing mushroom administration: a #case #report

https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2026.1813281/full

Transient multidomain functional improvement in advanced Alzheimer’s disease following high-dose #psilocybin-containing mushroom administration: a #case #report

https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2026.1813281/full

Transient multidomain functional improvement in advanced Alzheimer’s disease following high-dose #psilocybin-containing mushroom administration: a #case #report

https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2026.1813281/full

Transient multidomain functional improvement in advanced Alzheimer’s disease following high-dose #psilocybin-containing mushroom administration: a #case #report

https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2026.1813281/full

»Psilocybin mit begleitender Psychotherapie zeigt antidepressiven Effekt über zwölf Monate

Psilocybin mit begleitender Psychotherapie kann bei Menschen mit therapieresistenter Depression zu langfristigen Verbesserungen der depressiven Symptomatik führen. Das zeigt eine jetzt veröffentlichte Langzeitnachbeobachtung des Zentralinstituts für Seelische Gesundheit (ZI), der Charité – Universitätsmedizin Berlin und der MIND Foundation. Die antidepressiven Effekte hielten über einen Zeitraum von bis zu zwölf Monaten an. Nach Angaben der Forschenden handelt es sich um die bislang umfassendste Langzeituntersuchung einer klinischen Studie mit Psychedelika. Die Ergebnisse wurden in der renommierten Fachzeitschrift „Psychotherapy and Psychosomatics“ veröffentlicht.«
https://idw-online.de/de/news872727
🍄‍🟫⚕️🧠
#Psilocybin #Therapie

»Psilocybin mit begleitender Psychotherapie zeigt antidepressiven Effekt über zwölf Monate

Psilocybin mit begleitender Psychotherapie kann bei Menschen mit therapieresistenter Depression zu langfristigen Verbesserungen der depressiven Symptomatik führen. Das zeigt eine jetzt veröffentlichte Langzeitnachbeobachtung des Zentralinstituts für Seelische Gesundheit (ZI), der Charité – Universitätsmedizin Berlin und der MIND Foundation. Die antidepressiven Effekte hielten über einen Zeitraum von bis zu zwölf Monaten an. Nach Angaben der Forschenden handelt es sich um die bislang umfassendste Langzeituntersuchung einer klinischen Studie mit Psychedelika. Die Ergebnisse wurden in der renommierten Fachzeitschrift „Psychotherapy and Psychosomatics“ veröffentlicht.«
https://idw-online.de/de/news872727
🍄‍🟫⚕️🧠
#Psilocybin #Therapie

»Psilocybin mit begleitender Psychotherapie zeigt antidepressiven Effekt über zwölf Monate

Psilocybin mit begleitender Psychotherapie kann bei Menschen mit therapieresistenter Depression zu langfristigen Verbesserungen der depressiven Symptomatik führen. Das zeigt eine jetzt veröffentlichte Langzeitnachbeobachtung des Zentralinstituts für Seelische Gesundheit (ZI), der Charité – Universitätsmedizin Berlin und der MIND Foundation. Die antidepressiven Effekte hielten über einen Zeitraum von bis zu zwölf Monaten an. Nach Angaben der Forschenden handelt es sich um die bislang umfassendste Langzeituntersuchung einer klinischen Studie mit Psychedelika. Die Ergebnisse wurden in der renommierten Fachzeitschrift „Psychotherapy and Psychosomatics“ veröffentlicht.«
https://idw-online.de/de/news872727
🍄‍🟫⚕️🧠
#Psilocybin #Therapie

»Psilocybin mit begleitender Psychotherapie zeigt antidepressiven Effekt über zwölf Monate

Psilocybin mit begleitender Psychotherapie kann bei Menschen mit therapieresistenter Depression zu langfristigen Verbesserungen der depressiven Symptomatik führen. Das zeigt eine jetzt veröffentlichte Langzeitnachbeobachtung des Zentralinstituts für Seelische Gesundheit (ZI), der Charité – Universitätsmedizin Berlin und der MIND Foundation. Die antidepressiven Effekte hielten über einen Zeitraum von bis zu zwölf Monaten an. Nach Angaben der Forschenden handelt es sich um die bislang umfassendste Langzeituntersuchung einer klinischen Studie mit Psychedelika. Die Ergebnisse wurden in der renommierten Fachzeitschrift „Psychotherapy and Psychosomatics“ veröffentlicht.«
https://idw-online.de/de/news872727
🍄‍🟫⚕️🧠
#Psilocybin #Therapie

»Psilocybin mit begleitender Psychotherapie zeigt antidepressiven Effekt über zwölf Monate

Psilocybin mit begleitender Psychotherapie kann bei Menschen mit therapieresistenter Depression zu langfristigen Verbesserungen der depressiven Symptomatik führen. Das zeigt eine jetzt veröffentlichte Langzeitnachbeobachtung des Zentralinstituts für Seelische Gesundheit (ZI), der Charité – Universitätsmedizin Berlin und der MIND Foundation. Die antidepressiven Effekte hielten über einen Zeitraum von bis zu zwölf Monaten an. Nach Angaben der Forschenden handelt es sich um die bislang umfassendste Langzeituntersuchung einer klinischen Studie mit Psychedelika. Die Ergebnisse wurden in der renommierten Fachzeitschrift „Psychotherapy and Psychosomatics“ veröffentlicht.«
https://idw-online.de/de/news872727
🍄‍🟫⚕️🧠
#Psilocybin #Therapie

»Kokainabhängigkeit: Psilocybin fördert Abstinenz in Pilotstudie

Die einmalige Gabe von Psilocybin kann offenbar auch bei Menschen mit einer Kokainabhängigkeit, die bisher als kaum therapierbar eingestuft wird, die Erfolgschancen einer kognitiven Verhaltenstherapie verbessern. Das legen die Ergebnisse einer Pilotstudie nahe, über die in JAMA Network Open berichtet wird«

https://www.aerzteblatt.de/news/kokainabhangigkeit-psilocybin-fordert-abstinenz-in-pilotstudie-edcf1982-5936-48ac-9e8b-d58ed8e62b08
🍄‍🟫⚕️🧠
#Psilocybin #Therapie

»Kokainabhängigkeit: Psilocybin fördert Abstinenz in Pilotstudie

Die einmalige Gabe von Psilocybin kann offenbar auch bei Menschen mit einer Kokainabhängigkeit, die bisher als kaum therapierbar eingestuft wird, die Erfolgschancen einer kognitiven Verhaltenstherapie verbessern. Das legen die Ergebnisse einer Pilotstudie nahe, über die in JAMA Network Open berichtet wird«

https://www.aerzteblatt.de/news/kokainabhangigkeit-psilocybin-fordert-abstinenz-in-pilotstudie-edcf1982-5936-48ac-9e8b-d58ed8e62b08
🍄‍🟫⚕️🧠
#Psilocybin #Therapie

»Kokainabhängigkeit: Psilocybin fördert Abstinenz in Pilotstudie

Die einmalige Gabe von Psilocybin kann offenbar auch bei Menschen mit einer Kokainabhängigkeit, die bisher als kaum therapierbar eingestuft wird, die Erfolgschancen einer kognitiven Verhaltenstherapie verbessern. Das legen die Ergebnisse einer Pilotstudie nahe, über die in JAMA Network Open berichtet wird«

https://www.aerzteblatt.de/news/kokainabhangigkeit-psilocybin-fordert-abstinenz-in-pilotstudie-edcf1982-5936-48ac-9e8b-d58ed8e62b08
🍄‍🟫⚕️🧠
#Psilocybin #Therapie

»Kokainabhängigkeit: Psilocybin fördert Abstinenz in Pilotstudie

Die einmalige Gabe von Psilocybin kann offenbar auch bei Menschen mit einer Kokainabhängigkeit, die bisher als kaum therapierbar eingestuft wird, die Erfolgschancen einer kognitiven Verhaltenstherapie verbessern. Das legen die Ergebnisse einer Pilotstudie nahe, über die in JAMA Network Open berichtet wird«

https://www.aerzteblatt.de/news/kokainabhangigkeit-psilocybin-fordert-abstinenz-in-pilotstudie-edcf1982-5936-48ac-9e8b-d58ed8e62b08
🍄‍🟫⚕️🧠
#Psilocybin #Therapie

»Kokainabhängigkeit: Psilocybin fördert Abstinenz in Pilotstudie

Die einmalige Gabe von Psilocybin kann offenbar auch bei Menschen mit einer Kokainabhängigkeit, die bisher als kaum therapierbar eingestuft wird, die Erfolgschancen einer kognitiven Verhaltenstherapie verbessern. Das legen die Ergebnisse einer Pilotstudie nahe, über die in JAMA Network Open berichtet wird«

https://www.aerzteblatt.de/news/kokainabhangigkeit-psilocybin-fordert-abstinenz-in-pilotstudie-edcf1982-5936-48ac-9e8b-d58ed8e62b08
🍄‍🟫⚕️🧠
#Psilocybin #Therapie

https://www.europesays.com/at/221487/ Psychedelika fürs Gehirn: Forscher prüfen Schutz vor Alterung #Altern #Altersforschung #AT #Austria #Forschung #Gehirn #Gesundheit #Health #Neuroplastizität #Neurowissenschaft #Österreich #Pilze #Psilocybin #Psyche #Psychedelika #Psychologie #SmartUpNews #UniversityOfCaliforniaBerkeley

“People with childhood maltreatment histories, on average, report lower levels of PTSD symptoms, complex PTSD (#CPTSD) symptoms, and internalized shame and higher levels of connectedness to themselves, others, and the world after using psychedelics with therapeutic intent at organized group ceremonies or at raves or other electronic dance music events.”

https://www.psypost.org/taking-psychedelics-at-raves-and-ceremonies-may-help-heal-childhood-trauma/

#MDMA #LSD #Psilocybin

“People with childhood maltreatment histories, on average, report lower levels of PTSD symptoms, complex PTSD (#CPTSD) symptoms, and internalized shame and higher levels of connectedness to themselves, others, and the world after using psychedelics with therapeutic intent at organized group ceremonies or at raves or other electronic dance music events.”

https://www.psypost.org/taking-psychedelics-at-raves-and-ceremonies-may-help-heal-childhood-trauma/

#MDMA #LSD #Psilocybin